Hypermethylation of promoter regions of the APC1A and p16 INK4a genes in relation to prognosis and tumor characteristics in cervical cancer patients

International Journal of Oncology

Volumn 39, Issue 3, 2011, Pages 683-688

  Löf Öhlin, Zarah M ^a   Sorbe, Bengt ^a   Wingren, Sten ^b   Nilsson, Torbjörn K ^a,b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

Author keywords

APC1A; Cervical squamous cell carcinoma; DNA methylation; p16; Prognosis

Indexed keywords

PROTEIN P16;

ADENOCARCINOMA; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA EXTRACTION; DNA METHYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PYROSEQUENCING; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EPIGENOMICS; FEMALE; HUMANS; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 79959932532     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1078     Document Type: Article

References (43)

1. Das PM and Singal R: DNA methylation and cancer. J Clin Oncol 22: 4632-4642, 2004. (Pubitemid 41185132)
2. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21, 2002.
3. Preuss I, Eberhagen I, Haas S, et al: O6-methylguanine-DNA methyltransferase activity in breast and brain tumors. Int J Cancer 61: 321-326, 1995.
4. Newcomb EW, Alonso M, Sung T and Miller DC: Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. Hum Pathol 31: 115-119, 2000. (Pubitemid 30054396)
5. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993. (Pubitemid 24036021)
6. Song MS, Song SJ, Ayad NG, et al: The tumour suppressor RASSFlA regulates mitosis by inhibiting the APC-Cdc20 complex. Nature Cell Biol 6: 129-137, 2004. (Pubitemid 38425712)
7. Rubinfeld B, Souza B, Albert I, et al: Association of the APC gene product with beta-catenin. Science 262: 1731-1734, 1993. (Pubitemid 24030096)
8. Su LK, Vogelstein B and Kinzler KW: Association of the APC tumor suppressor protein with catenins. Science 262: 1734-1737, 1993. (Pubitemid 24030097)
9. van den Donk M, Pellis L, Crott JW, et al: Folic acid and vitamin B-12 supplementation does not favorably influence uracil incorporation and promoter methylation in rectal mucosa DNA of subjects with previous colorectal adenomas. J Nutr 137 2114-2120, 2007. (Pubitemid 47367274)
10. van Engeland M, Weijenberg MP, Roemen GM, et al: Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res 63: 3133-3137, 2003. (Pubitemid 36735864)
11. Löf-Öhlin Z and Nilsson T: Development of Pyrosequencing assays to study promoter CpG site methylation of the O6-MGMT, hMLH1, p14ARF, p16INK4a, RASSF1A, and APC1A genes. Oncol Rep 21: 721-729, 2009.
12. Colella S, Shen L, Baggerly KA, Issa JP and Krahe R: Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 35: 146-150, 2003. (Pubitemid 36828724)
13. Uhlmann K, Brinckmann A, Toliat MR, Ritter H and Nurnberg P: Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis 23: 4072-4079, 2002. (Pubitemid 36131460)
14. Tost J and Gut IG: Analysis of gene-specific DNA methylation patterns by pyrosequencing™ technology. Methods Mol Biol 373: 89-102, 2006.
15. Dupont JM, Tost J, Jammes H and Gut IG: De novo quantitative bisulfite sequencing using the pyrosequencing technology. Anal Biochem 333: 119-127, 2004. (Pubitemid 39209229)
16. Konishi K, Shen L, Wang S, Meltzer SJ, Harpaz N and Issa JP: Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology 132: 1254-1260, 2007. (Pubitemid 46627571)
17. Fontaniere S, Tost J, Wierinckx A, et al: Gene expression profiling in insulinomas of Men1 beta-cell mutant mice reveals early genetic and epigenetic events involved in pancreatic beta-cell tumorigenesis. Endocr Relat Cancer 13: 1223-1236, 2006. (Pubitemid 46212576)
18. Shames DS, Minna JD and Gazdar AF: Methods for detecting DNA methylation in tumors: From bench to bedside. Cancer Lett 251: 187-198, 2007. (Pubitemid 46669792)
19. Chan TL, Yuen ST, Kong CK, et al: Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 38: 1178-1183, 2006. (Pubitemid 44470364)
20. Brakensiek K, Wingen LU, Langer F, Kreipe H and Lehmann U: Quantitative high-resolution CpG island mapping with Pyrosequencing reveals disease-specific methylation patterns of the CDKN2B gene in myelodysplastic syndrome and myeloid leukemia. Clin Chem 53: 17-23, 2007. (Pubitemid 46047759)
21. Wang LG, Beklemisheva A, Liu XM, Ferrari AC, Feng J and Chiao JW: Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol Carcinog 46: 24-31, 2007. (Pubitemid 46095230)
22. Cheng YW, Shawber C, Notterman D, Paty P and Barany F: Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay. Genome Res 16: 282-289, 2006. (Pubitemid 43200277)
23. Bollati V, Baccarelli A, Hou L, et al: Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res 67: 876-880, 2007.
24. Issa JP, Gharibyan V, Cortes J, et al: Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23: 3948-3956, 2005. (Pubitemid 46218698)
25. Oki Y, Kantarjian HM, Gharibyan V, et al: Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109: 899-906, 2007. (Pubitemid 46333532)
26. White HE, Durston VJ, Harvey JF and Cross NC: Quantitative analysis of SNRPN (correction of SRNPN) gene methylation by pyrosequencing as a diagnostic test for Prader-Willi syndrome and Angelman syndrome. Clin Chem 52: 1005-1013, 2006. (Pubitemid 43794410)
27. Kuratomi G, Iwamoto K, Bundo M, et al: Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins. Mol Psychiatry 13: 429-441, 2008. (Pubitemid 351399814)
28. Mill J, Dempster E, Caspi A, Williams B, Moffitt T and Craig I: Evidence for monozygotic twin (MZ) discordance in methylation level at two CpG sites in the promoter region of the catechol-O-methyltransferase (COMT) gene. Am J Med Genet B Neuropsychiatr Genet 141: 421-425, 2006. (Pubitemid 43872897)
29. Lee JS, Fackler MJ, Teo WW, et al: Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis. Cancer Biol Ther 7: 1398-1346, 2007.
30. Wu JM, Fackler MJ, Halushka MK, et al: Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14: 1938-1946, 2008.
31. Van der Auwera I, Van Laere SJ, Van den Bosch SM, et al: Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer 99: 1735-1742, 2008.
32. Henrique R, Ribeiro FR, Fonseca D, et al: High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 13: 6122-6129, 2007. (Pubitemid 350075071)
33. Richiardi L, Fiano V, Vizzini L, et al: Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 27: 3161-3168, 2009.
34. Brock MV, Hooker CM, Ota-Machida E, et al: DNA methylation markers and early recurrence in stage I lung cancer. NEJM 358: 1118-1128, 2008. (Pubitemid 351398486)
35. Ho CM, Lai HC, Huang SH, Chien TY, Lin MC and Chang SF: Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma. Eur J Clin Invest 40: 310-318, 2010.
36. Ignatov A, Bischoff J, Ignatov T, et al: APC promoter hypermethylation is an early event in endometrial tumorigenesis. Cancer Sci 101: 321-327, 2010.
37. Supic G, Kozomara R, Brankovic-Magic M, Jovic N and Magic Z: Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral Oncol 45: 1051-1057, 2009.
38. Kim YT, Park JY, Jeon YK, et al: Aberrant promoter CpG island hypermethylation of the adenomatosis polyposis coli gene can serve as a good prognostic factor by affecting lymph node metastasis in squamous cell carcinoma of the esophagus. Dis Esophag 22: 143-150, 2009.
39. Csepregi A, Röcken C, Hoffmann J, et al: APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol 134: 579-589, 2008.
40. Chen SP, Chiu SC, Wu CC, et al: The association of methylation in the promoter of APC and MGMT and the prognosis of Taiwanese CRC patients. Genet Test Mol Biomarkers 13: 67-71, 2009.
41. Song Y and Zhang C: Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Cancer Chemother Pharmacol 63: 605-613, 2009.
42. Cordero J, Vidal M and Sansom O: APC as a master regulator of intestinal homeostasis and transformation. Cell Cycle 8: 2927-2932, 2008.
43. Phelps RA, Chidester S, Dehghanizadeh S, et al: A two-step model for colon adenoma initiation and progression caused by APC loss. Cell 137: 623-634, 2009.